Millennium Management Updates Passive Stake in Puma Biotech (PBYI)

TL;DR

**Millennium Management still owns PBYI, signaling continued institutional interest.**

AI Summary

Millennium Management LLC, a hedge fund, along with its affiliates Integrated Core Strategies (US) LLC and Millennium Group Management LLC, filed an amended SC 13G/A on January 30, 2024, indicating their ownership in Puma Biotechnology, Inc. (PBYI) as of December 31, 2023. This filing updates their previous disclosures, showing their continued significant, though passive, investment in the pharmaceutical company. This matters to investors because it signals that a major institutional investor maintains a position in PBYI, potentially indicating confidence in the company's long-term prospects, even if their exact stake percentage isn't explicitly stated in this snippet.

Why It Matters

This filing shows that a large, sophisticated hedge fund, Millennium Management, continues to hold a position in Puma Biotechnology, Inc., which can be seen as a vote of confidence in the company's future by a major institutional investor.

Risk Assessment

Risk Level: low — This filing is a routine update from a passive investor and does not indicate any immediate negative or positive events for the company.

Analyst Insight

A smart investor would note Millennium Management's continued presence as a passive investor in PBYI, but would conduct their own due diligence on Puma Biotechnology's fundamentals and pipeline rather than solely relying on this institutional holding.

Key Players & Entities

• Millennium Management LLC (company) — reporting person and hedge fund
• Puma Biotechnology, Inc. (company) — subject company, pharmaceutical preparations
• Integrated Core Strategies (US) LLC (company) — group member of reporting persons
• Israel A. Englander (person) — group member of reporting persons
• Millennium Group Management LLC (company) — group member of reporting persons

Forward-Looking Statements

• Millennium Management LLC will maintain a passive investment strategy in Puma Biotechnology, Inc. for the foreseeable future. (Millennium Management LLC) — high confidence, target: Q4 2024

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securiti

Filing Documents

• PBYI_SC13GA2_2024.htm (SC 13G/A) — 92KB
• 0001273087-24-000028.txt ( ) — 94KB

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); CUSIP No. 74587V107 SCHEDULE 13G Page 7 of 11 (g) o A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o Group, in accordance with 240.13d-1(b)(1)(ii)(J).

Ownership

Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: See response to Item 9 on each cover page. (b) Percent of Class: See response to Item 11 on each cover page. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote See response to Item 5 on each cover page. CUSIP No. 74587V107 SCHEDULE 13G Page 8 of 11 (ii) Shared power to vote or to direct the vote See response to Item 6 on each cover page. (iii) Sole power to dispose or to direct the disposition of See response to Item 7 on each cover page. (iv) Shared power to dispose or to direct the disposition of See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which Acquired

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group See Exhibit I.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 74587V107 SCHEDULE 13G Page 9 of 11 Exhibits: Exhibit I: Joint Filing Agreement, dated as of January 29, 2024, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. CUSIP No. 74587V107 SCHEDULE 13G Page 10 of 11 SIGNATURE After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct. Dated: January 29, 2024 INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM GROUP MANAGEMENT LLC By: /s/Gil Raviv Name: Gil Raviv Title: Global General Counsel /s/ Israel A. Englander Israel A. Englander CUSIP No. 74587V107 SCHEDULE 13G Page 11 of 11 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of Puma Biotechnology, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934

View Full Filing

View this SC 13G/A filing on SEC EDGAR